AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex.
Marshall
Kathryn M
KM
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
Holden
Joseph A
JA
Koller
Avi
A
Kashman
Yoel
Y
Copp
Brent R
BR
Barrows
Louis R
LR
D000166:Acridines / Q000737:chemistry* / Q000633:toxicity*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000633:toxicity; D016466:CHO Cells; D045744:Cell Line, Tumor; D006224:Cricetinae; D004249:DNA Damage; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000633:toxicity; D004795:Enzyme Stability / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007364:Intercalating Agents / Q000737:chemistry* / Q000633:toxicity*; D010618:Phenanthrolines / Q000737:chemistry* / Q000633:toxicity*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
C499812:AK37 compound; D000166:Acridines; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007364:Intercalating Agents; D010618:Phenanthrolines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; C475900:pyridoacridine; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II